KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Liabilities: 2009-2025

Historic Total Liabilities for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2025 value amounting to $7.4 billion.

  • Jazz Pharmaceuticals' Total Liabilities fell 8.50% to $7.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 billion, marking a year-over-year decrease of 8.50%. This contributed to the annual value of $7.9 billion for FY2024, which is 3.42% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Total Liabilities of $7.4 billion as of Q3 2025, which was up 2.21% from $7.2 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' Total Liabilities' 5-year high stood at $9.1 billion during Q2 2021, with a 5-year trough of $3.0 billion in Q1 2021.
  • Over the past 3 years, Jazz Pharmaceuticals' median Total Liabilities value was $7.7 billion (recorded in 2023), while the average stood at $7.6 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Total Liabilities surged by 210.51% in 2021, and later dropped by 11.92% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Total Liabilities (Quarterly) stood at $8.3 billion in 2021, then fell by 7.01% to $7.7 billion in 2022, then fell by 1.20% to $7.7 billion in 2023, then increased by 3.42% to $7.9 billion in 2024, then decreased by 8.50% to $7.4 billion in 2025.
  • Its Total Liabilities stands at $7.4 billion for Q3 2025, versus $7.2 billion for Q2 2025 and $7.4 billion for Q1 2025.